

REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/US2005/007822 into the U.S. National Phase of prosecution. In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Entry of this amendment into the record is requested.

Claims 2 and 3 have been amended.

Respectfully submitted,

/SomaGSimon/

Soma G. Simon
Attorney for Applicants
Registration No. 37,444

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5019
Facsimile (610) 270-5090

N:\SOMA\CASES\PU60782\prel_amend.doc

ABSTRACT OF THE DISCLOSURE

Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.